Despite posting the sixth biggest loss in UK corporate history, shares in Tesco (LSE: TSCO) are flat today at the time of writing. Thats in spite of the company reporting a whopping 6.4bn loss for the last financial year, with trading conditions remaining challenging and the companys turnaround plans taking time to have a positive effect.
This, then, is likely to be the time when many investors feel pessimistic regarding the companys future prospects. However, now could be the perfect time to add Tesco to your portfolio. Heres why.
Although the supermarket sector is experiencing a challenging period, with incumbents such as Tesco seemingly running hard just to stand still, the major reason for Tescos horror show annual performance is asset write downs. In fact, Tesco has written down its fixed asset base by 4.7bn, which is reflective of anticipated difficult trading conditions in future.
And, there are other one-off items, too, with Tesco experiencing an impairment of goodwill of 880m, a reduction in the value of its stock of 570m, as well as vast restructuring costs of over 400m. Together, they amount to 7bn of one-off items, which clearly makes the companys results appear disastrous but, looking ahead, by their very nature they are not expected to recur.
A New Start
As with any company that is going through a tough period and which appoints a new management team, there is often a lot of bad news in the early days. This happens in every sector in every part of the world and, while it can lead to investor sentiment declining, in the long run it is the most successful formula for turning a business around. Thats because it allows the company to begin afresh and to move forward with the changes that are necessary. As such, the magnitude of losses announced by Tesco today is perhaps to have been expected, given the problems which exist within the supermarket space at the present time.
Of course, excluding all of the one off items mentioned above means that Tesco remained profitable last year. Certainly, its bottom line fell by 58% to 1.4bn, but this was very much in-line with expectations. And, with Tesco delivering its first like-for-like sales volume growth in the UK for over four years, its strategy of improving customer service and better targeted price reductions appear to be increasing footfall and having a positive impact on customers. Furthermore, plans to rationalise the business are likely to make Tesco more focused and more efficient which, in time, is likely to improve profitability.
While todays results are clearly disappointing, the market was anticipating a very tough year. The key driver for Tescos share price, of course, is what happens moving forward as opposed to how difficult the past has been. And, on this front, the company appears to have the right strategy with which to make a strong comeback over the medium to long term. This will undoubtedly be aided by better trading conditions, with real terms wage growth likely to ease pressure on sales volumes and improve the companys outlook.
So, while Tescos share price has risen by an impressive 23% year-to-date, its forecasts and valuation indicate that there is much more to come. For example, it is expected to increase its net profit by 15% this year, and by a further 28% next year. And, with Tesco having a price to earnings (P/E) ratio of 21.7, it appears to offer excellent value for money given its very positive outlook.
Of course, Tesco isn’t the only company that could be worth buying at the present time. With that in mind, the analysts at The Motley Fool have written a free and without obligation guide called 5 Shares You Can Retire On.
The 5 companies in question offer stunning dividend yields, have fantastic long term potential, and trade at very appealing valuations. As such, they could deliver excellent returns and provide your portfolio with a major boost in 2015 and beyond.
Click here to find out all about them – it’s completely free and without obligation to do so.
A Bigger Piece Of A 4 Billion Pie?
This fast-growing pharmaceutical business could be all set to become a potential blockbuster.
Recent approvals in Europe and Japan of its latest niche drug means it can now tap a market worth an estimated 4bn a year potentially doubling its sales in the process.
Thats just one of the reasons why our Motley Fool analysts think this under-the-radar innovator could be among the big winners of tomorrow.
To find out more, click here to download this FREE small-cap report now